Dr. Olujide A. Bamiro, MD

Dr. Bamiro practices at Wellstar Spalding Medical Center - Mammography in Griffin, Georgia.

Dr. Bamiro's NPI, 1750341293, was assigned on March 27, 2006. Dr. Bamiro holds Georgia license 059369.

Dr. Bamiro's primary practice is Wellstar Spalding Medical Center - Mammography, at 601 South 8th St., Griffin, GA 30224. The practice phone is (470) 935-4483.

Dr. Bamiro's primary practice is Wellstar Spalding Medical Center - Mammography in Griffin, Georgia. Dr. Bamiro is also affiliated with Wellstar Spalding Medical Center. The medical group on file is Wellstar Medical Group. Dmand AI also links Dr. Bamiro to 4 more hospitals, 9 medical groups and 1 group practice or clinic, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Bamiro practices, 7 sites in all. Vendor and product names are available with a free account.

Hospitalist is Dr. Bamiro's primary specialty in the NPI Registry, under taxonomy code 208M00000X. Dmand AI has Dr. Bamiro's licenses on file in 2 states: Georgia and Ohio.

CMS data shows 774 Medicare services from Dr. Bamiro across 5 procedure codes in 2024, for 285 Medicare patients. Medicare paid $55,590 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 285 Medicare patients who saw Dr. Bamiro in 2024. The largest group is 75 to 84, with 100 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 27% are also on Medicaid. Their average risk score is 2.56, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Bamiro's median patient age at 70, with 54% women.

In 2024, Dr. Bamiro wrote 452 Medicare Part D claims for 215 patients. 88% of them were for generic drugs. CMS names the drug for 200 of them, across 12 drugs with 11 or more claims each, at $14,792 in total drug cost. In 2023, CMS named 90 claims across 6 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 95 out of 100 for Dr. Bamiro for performance year 2024, reported through an alternative payment model (APM). Dr. Bamiro accepts Medicare assignment, so Medicare's approved amount is taken as full payment.

CMS Open Payments shows 2 general payments to Dr. Bamiro from 2 drug and device companies from 2019 to 2023. Food and beverage make up the largest share, 100% of the total. AstraZeneca Pharmaceuticals LP paid the most, $24.